R&D at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vera Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vera Therapeutics's R&D?
- Vera Therapeutics (VERA) reported R&D of $86.01M in Q1 2026.
- How has Vera Therapeutics's R&D changed year-over-year?
- Vera Therapeutics's R&D increased by 108.4% year-over-year, from $41.28M to $86.01M.
- What is the long-term trend for Vera Therapeutics's R&D?
- Over 4 years (2021 to 2025), Vera Therapeutics's R&D has grown at a 75.9% compound annual growth rate (CAGR), from $22.48M to $215.26M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.